TGFB1 and neoplasm: This approach resulted in a 50% knockdown of TGF-β in the tumor tissues of subcutaneous B16F10 murine melanoma-bearing mice, increased CD8+ effector T cell infiltration and decreased Treg numbers, compared with using a lipid-based NP vaccine system delivering Trp2 peptides (as tumor antigens) and CpG oligonucleotides (as adjuvants) [232].